Torino ALS Center (CRESLA)

University of Torino

The Torino ALS Center (CRESLA) performs basic and clinical research, while at the same time providing care for ALS patients.

Cresla_footer
University of Torino

Our centre is based in the largest public hospital in Italy (the “Città della Salute e della Scienza” hospital of Torino). We follow about 350 patients each year, both locally and nationwide. We have a diagnostic laboratory and a molecular genetics laboratory. Our scientific studies include both clinical and basic research of ALS. In the last decade, we have participated in 5 large international randomized clinical trials on innovative drugs in ALS. We have a multidisciplinary group and a daily ALS clinic. We also provide psychological, neuropsychological and neurophysiological services.

Contact
Location
University of Turin, Turin, Via Cherasco 15, 10126, Torino, Italy

Our Specialists

Adriano Chiò

Professor of Neurology

Adriano Chiò is a neurologist currently working in Torino, Italy. He is […]

Adriano Chiò
Current trials
Recruiting
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Recruiting
Phase iii

ADORE Trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Recruiting
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more